WHO Launches Program to Counter Drug-Resistant Malaria

On World Malaria Day, the World Health Organization has launched an emergency program in Phnom Penh to tackle a worrying regional trend – a strain of malaria that is proving resistant to the most important anti-malarial drug.

Six years ago, health researchers were worried after a strain of malaria in western Cambodia began to show resistance to the world’s key malaria treatment – Artemisinin-based Combination Therapy, known as ACT.

In response, the Cambodian government and its health partners, including the World Health Organization, put in place a program to prevent the resistant strain (falciparum malaria) from spreading within Cambodia and beyond its borders.

That program appears to have contained the resistant strain. But Thailand, Burma and Vietnam have reported pockets of artemisinin-resistant malaria strains.

The WHO malaria specialist in Phnom Penh, Stephen Bjorge, said it is likely the strains in those countries arose independently of Cambodia’s – which means the containment efforts have worked.

But because artemisinin is the standard treatment, it is important the resistant strains in all of these areas are contained and then eradicated. That is the purpose of a three-year, $400-million program the World Health Organization announced Thursday.

“The risks are significant – not only are they significant for the region in terms of having a reversal of the gains that have been made against malaria, but they are actually significant globally,” said Robert Newman, director of the WHO’s Global Malaria Program. “If history is any guide, if we were not to contain this problem then it is very likely to spread elsewhere. Especially risky is to sub-Saharan Africa, where the greatest burden still exists. And, if we were to lose the efficacy of the ACTs today, this really would be a public health catastrophe in Africa.”

The WHO-led program is being funded by the Global Fund, the Bill & Melinda Gates Foundation and by the Australian government’s development arm called AusAID.

It will cover six countries: the four where resistance has already been found, as well as two more considered to be “at risk” from the resistant strain: Laos and an area of southern China.

Newman said some of the lessons learned from Cambodia’s efforts are being used.

“This is not starting from zero,” he explained. “It is building on the experience initially on the Cambodia-Thailand border where those countries gained a lot of experience in how to reach the populations that are actually most difficult to reach – migrant and mobile populations, how to use village health care workers, how to more aggressively remove substandard medicines from the market.”

The program will distribute insecticide-treated bed nets; monitor fake drugs; ensure people have access to reliable testing and treatment; and track the disease. Migrant communities and people living in border regions will be key targets of the program.

AusAID has provided $5 million of funding for the program.

“Well, our initial funding is fixed, but the reality is Australia is part of this region,” said AusAID’s principal health advisor Ben David. “We are part of the Asia-Pacific and we see this as a critical investment to protect the poor in the region from malaria, but also to protect the interests of countries because if this problem gets out of control and we see malaria drug resistance spread in the region and beyond, then we are in to face a big set of problems.”

David says, last year, malaria killed 42,000 people in the Asia-Pacific region and more than half a million worldwide, most of them children in Africa.

Recent years have seen good progress in tackling malaria, but the WHO warns that could be undone should the resistant strains escape the current pockets in the countries of the Greater Mekong sub-region.

David believes governments will do their part to prevent the spread.

“It has actually got significant economic implications, if this problem of resistance continues. So, we really need to make the economic case to governments to continue to invest in this problem,” he added.

The chloroquine-resistant malaria strain has caused millions of deaths globally since it emerged 60 years ago from the forests of western Cambodia.

The World Health Organization warns the world cannot afford a similar repeat outbreak by allowing the new strain or strains of artemisinin-resistant malaria to escape the region.

Source: VOA News

New Partners Join the Asia Pacific Malaria Elimination Network (APMEN)

The Asia Pacific Malaria Elimination Network (APMEN) has announced two new Partner Institutions have joined the organization: The Mahidol Vivax Research Center and the Malaria Research Centre, Universiti Malaysia Sarawak.

The Mahidol Vivax Research Center (MVRC) established in March 2011 is dedicated to the study of Plasmodium vivax and non falciparum malaria. Its establishment at Mahidol University in Thailand is important to the region, as Mahidol has a long record in the field of tropical disease medicine and research. Mahidol Vivax Research Center was initiated by the Dean of the Faculty of Tropical Medicine, Mahidol University, Associate Professor Pratap Singhasivanon and is directed by Dr. Jetsumon Prachumsri, formerly the leader of malaria research at the Armed Forces Research Institutes of Medical Sciences (AFRIMS) and APMEN Partner Institution representative.

The Malaria Research Centre was established at the Universiti Malaysia Sarawak in 2006 in recognition of the major contribution to malaria research by Professor Balbir Singh, Professor Janet Cox-Singh, and co-researchers at the Malaria Research Laboratory in the Faculty of Medicine and Health Sciences. MRC-UNIMAS is known for its work on Plasmodium knowlesi that was recognised by the World Health Organization (WHO) in 2008 as the fifth species of Plasmodia parasite to infect humans in the wild.

MRC-UNIMAS found that many malaria infections in Sarawak, Malaysia, had been incorrectly diagnosed and a major cause of malaria was Plasmodium knowlesi that is transmitted via the bit of an Anopheline mosquito from long-tail and pig-tail macaques. P knowlesi has also been reported in other parts of Malaysia, Indonesia, and Philippines and may be endemic in more countries in Southeast Asia. The final elimination of malaria in the Asia Pacific region will depend on a greater understanding of P knowlesi and how we can target this zoonosis.

The Malaria Research Centre, Universiti Malaysia Sarawak and the Mahidol Vivax Research Center have already supported APMEN through their active participation at last year’s annual meeting in Kota Kinabalu, Malaysia.

The fourth annual APMEN Annual Meeting will be held in May 2012 in Seoul, Republic of Korea. This year’s meeting will focus on how to sustain the gains made in the elimination of malaria and the importance in the coming years of maintaining successful approaches and their support. The region has many challenges to face in malaria elimination, in particular P. vivax, a type of malaria that is more difficult to diagnose and treat than P falciparum, the type of malaria most often discussed at a global level. APMEN through its information exchange, capacity building, and evidence building and advocacy activities is committed to supporting and maintaining elimination efforts in the Asia Pacific Region.

About the Asia Pacific Malaria Elimination Network
The Asia Pacific Malaria Elimination Network (APMEN) was established in 2009 to bring attention and support to the under-appreciated and little-known work of malaria elimination in Asia Pacific, with a particular focus on Plasmodium vivax.

APMEN is composed of 12 Asia Pacific countries (Bhutan, Cambodia, China, Democratic People’s Republic of Korea, Indonesia, Malaysia, Philippines, Republic of Korea, the Solomon Islands, Sri Lanka, Thailand, and Vanuatu) that are pursuing malaria elimination, as well as leaders and experts from key multilateral and academic agencies. The mission of this diverse but cohesive Network is to collaboratively address the unique challenges of malaria elimination in the region through leadership, advocacy, capacity building, knowledge exchange, and building the evidence base.

Development of the Network took place in 2008 through the leadership of the UCSF Global Health Group (GHG) and the School of Population Health, University of Queensland (SPH/UQ). APMEN collaborates closely with the WHO and is supported by the Australian Government through its international aid agency AusAID with a commitment of nearly $7 million for ongoing support to the Network. This complements Australia’s overall support for malaria control and elimination in the Asia Pacific and globally.

Source: Asia Pacific Malaria Elimination Network (APMEN)